Luke Düster is a member of CRG’s Founders Group and serves as Partner and member of CRG’s investment committee. Mr. Düster leads CRG’s investment process from sourcing and due diligence through realization. He is also responsible for portfolio management and portfolio company exits. Mr. Düster also serves on the board of directors of several CRG portfolio companies, both as a director and as an observer, and serves portfolio company senior management teams as an advisor on financial, strategic and operational initiatives. He has led investments in companies such as Neotract, Nevro, Omeros, Synergy Pharmaceuticals, Strongbridge Biopharma, Silk Road Medical, NanoString Technologies and many others. Prior to CRG, Mr. Düster was an investment banker at Harris Williams & Co., where he advised private equity and corporate clients across a broad range of M&A assignments. Mr. Düster also held investment banking roles at the Wallach Company, a regional investment banking boutique, and at the Nord Companies, a healthcare advisory firm. Mr. Düster received a bachelor’s degree from the University of Colorado at Boulder in 1997, where he graduated summa cum laude. He received an M.B.A with honors from the Wharton School at the University of Pennsylvania in 2004.